On a day when the Dow Jones Industrial Average
But instead, let's focus on what went right. We have a duo of biotechs that had a great showing, along with a medical-device maker popping after hours.
Investors in little-known ARCA Biopharma are 43% richer than they were when they woke up, all thanks to a positive trial result. The company's drug candidate, GencaroTM, is hoping to carve out space in the large and lucrative atrial fibrillation market. It had a 74% reduction in new a-fib onsets for patients with a relatively common genotype.
Don't feel bad if you've never heard of ARCA. Even after its rocket shot, the company's market cap is below $20 million. Considering a-fib treatments are where heavyweights like Bristol-Myers Squibb
Meanwhile, BioSante Pharmaceuticals
Finaly, Zoll Medical
For a handy way to keep track of the companies mentioned here, add them to our free My Watchlist feature:
David Williamson owns shares of Johnson & Johnson, but he holds no other position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.